Advertisement

Advertisement

Sarcoma

Dactinomycin Formulation Gets Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to NanoSmart Pharmaceuticals’ novel formulation of dactinomycin for the treatment of Ewing sarcoma, a rare type of childhood bone cancer. The designation was granted on the basis of a plausible hypothesis that the novel ...

Sarcoma

FDA Approves Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

The U.S. Food and Drug Administration has approved the novel chemotherapy drug trabectedin ­(Yondelis) for the treatment of specific soft-tissue sarcomas—liposarcoma and leiomyosarcoma—that are unresectable or metastatic. Trabectedin is a novel marine antineoplastic alkaloid with a unique mechanism ...

Sarcoma

Trabectedin in Unresectable or Metastatic Liposarcoma or Leiomyosarcoma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 23, 2015, trabectedin (Yondelis) was approved for the...

Sarcoma

Trabectedin in Liposarcoma/Leiomyosarcoma: The Drug Is Approved, Now the Real Drug Development Begins!

Led by George Demetri, MD, of Dana-Farber Cancer Institute, Boston, expert medical oncology investigators from leading academic sarcoma centers and Janssen Pharmaceuticals employees performed a phase III trial in order to provide evidence for the U.S. Food and Drug Administration (FDA) approval of...

Sarcoma

Improved Progression-Free Survival With Trabectedin vs Dacarbazine After Chemotherapy Failure in Liposarcoma or Leiomyosarcoma

In a phase III trial reported in the Journal of Clinical Oncology, George D. Demetri, MD, of Harvard Medical School and Dana-Farber Cancer Institute, Boston, and colleagues found that treatment with trabectedin (Yondelis) significantly improved progression-free survival vs dacarbazine in patients...

Sarcoma

Researcher Spotlight: Conquering Cancer With Dr. Heske

Sometimes, cancer treatments that initially appear promising begin to lose their effectiveness. This is due to the ability diseases like cancer have to develop resistance to treatments over time and, essentially, outsmart them. But what if there were ways to ensure this didn’t happen? What if...

sarcoma

Good Outcomes With Intensive, Interval-Compressed Chemotherapy and Irinotecan as Radiosensitizer in High-Risk Rhabdomyosarcoma

As reported in the Journal of Clinical Oncology by Weigel et al in the Children’s Oncology Group, a strategy of dose intensification and interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer has been found to ...

sarcoma

FDA Approves Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

The U.S. Food and Drug Administration today approved the chemotherapy drug trabectedin (Yondelis) for the treatment of specific soft-tissue sarcomas—liposarcoma and leiomyosarcoma—that are unresectable or metastatic. This treatment is approved for patients who previously received...

sarcoma

Phase IIb Trial Shows Improved Progression-Free Survival With First-Line Aldoxorubicin vs Doxorubicin in Advanced Soft-Tissue Sarcoma

In a randomized phase IIb trial reported in JAMA Oncology, Chawla et al found that aldoxorubicin—a novel albumin-binding prodrug of doxorubicin—produced longer progression-free survival than doxorubicin as first-line treatment for metastatic or locally advanced unresectable soft-tissue...

sarcoma

Improved Progression-Free Survival With Trabectedin vs Dacarbazine After Conventional Chemotherapy in Advanced Liposarcoma or Leiomyosarcoma

In a phase III trial reported in the Journal of Clinical Oncology, Demetri et al found that treatment with trabectedin significantly improved progression-free survival vs dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior conventional chemotherapy. Interim analysis of...

sarcoma

French Phase II Trial Suggests No Benefit of Adding Bevacizumab to Paclitaxel in Advanced Angiosarcoma

In a French phase II trial reported in the Journal of Clinical Oncology, Ray-Coquard et al found no apparent benefit of paclitaxel plus bevacizumab (Avastin) compared with weekly paclitaxel in patients with inoperable locally advanced or metastatic angiosarcoma. Study Details In this...

sarcoma

FDA Grants Orphan Drug Designation to Novel Dactinomycin Formulation for Ewing Sarcoma

The FDA has granted Orphan Drug designation to NanoSmart Pharmaceuticals’ novel formulation of dactinomycin for the treatment of Ewing sarcoma, a rare type of childhood bone cancer. The designation was granted on the basis of a plausible hypothesis that the novel formulation, which uses...

sarcoma
sarcoma

Addition of Interferon Alfa-2b to MAP Does Not Meet Event-Free Survival Objective in Osteosarcoma With Good Response to Preoperative MAP

In the phase III EURAMOS-1 trial reported in the Journal of Clinical Oncology, Bielack et al found that the addition of postoperative pegylated interferon alfa-2b (Pegintron, Sylatron) to MAP (methotrexate, doxorubicin, and cisplatin) in patients with osteosarcoma showing good histologic response...

sarcoma

ASCO 2015: Eribulin Extends Overall Survival for Heavily Pretreated Patients With Advanced Liposarcoma and Leiomyosarcoma

Heavily pretreated patients with intermediate- or high-grade liposarcoma or leiomyosarcoma had a 2-month increase in median overall survival when subsequently treated with eribulin (Halaven) rather than the standard drug dacarbazine. “For a disease where so few treatment options exist, a...

solid tumors
issues in oncology
sarcoma
issues in oncology

Population-Based Study Finds Patients With Gastrointestinal Tumors at Higher Risk of Other Cancers

Researchers at the University of California (UC) San Diego School of Medicine conducted the first population-based study that characterizes the association and temporal relationship between gastrointestinal stromal tumors (GIST) and other cancers. The results, published by Murphy et al in Cancer,...

gynecologic cancer
sarcoma

American College of Physicians Releases Best Practice Advice for Cervical Cancer Screening in Average-Risk Women

The American College of Physicians (ACP) released its clinical advice for cervical cancer screening in asymptomatic, average-risk women 21 years or older. Women at average risk are defined as those with no history of a precancerous lesion (cervical intraepithelial neoplasia grade 2 or a more severe ...

sarcoma

Key Tumor-Cell Proliferation Mechanism Identified in Pediatric Bone Cancers

A particular molecular pathway permits stem cells in pediatric bone cancers to grow rapidly and aggressively, according to researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. These findings were published by Basu-Roy et al in Nature Communications. Study...

sarcoma

Persistence of HER2-Specific CAR T Cells in HER2‑Positive Sarcoma

In a phase I/II study reported in Journal of Clinical Oncology, Ahmed et al found that infusion of T cells expressing HER2-specific chimeric antigen receptor (CAR) with a CD28.ζ signaling domain (HER2-CAR T cells) could produce persistent CAR T cell levels for ≥ 6 weeks in patients with...

gynecologic cancer
sarcoma

No Benefit of Adding Bevacizumab to First-Line Gemcitabine-Docetaxel in Metastatic Uterine Leiomyosarcoma

In a phase III NRG Oncology/Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Hensley et al found no benefit of adding bevacizumab (Avastin) to first-line gemcitabine-docetaxel in patients with metastatic uterine leiomyosarcoma. Study Details In this...

sarcoma

Reduction in Late Toxicities With Preoperative Image-Guided Radiation Therapy to Reduced Target Volume in Patients With Extremity Sarcoma

As reported in the Journal of Clinical Oncology by Wang et al, the incidence of late toxicity among patients with extremity soft-tissue sarcoma receiving preoperative image-guided radiotherapy to a reduced target volume in the phase II Radiation Therapy Oncology Group (RTOG) 0630 trial was lower...

sarcoma

FDA Grants Priority Review for Trabectedin for the Treatment of Patients With Advanced Soft-Tissue Sarcoma

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for trabectedin to treat patients with advanced soft-tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have...

sarcoma

Sorafenib Plus Everolimus Shows Some Activity in Progressive Unresectable High-Grade Osteosarcoma

In an Italian Sarcoma Group phase II study reported in The Lancet Oncology, Grignani et al found that the combination of sorafenib (Nexavar) and everolimus (Afinitor) was active in unresectable high-grade osteosarcoma progressing after standard treatment, but did not produce the study goal of ≥...

cns cancers
pancreatic cancer
issues in oncology
sarcoma

Researchers Identify Potential Treatment Targeting Proliferation Pathway in Some Aggressive Tumors

Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...

sarcoma
issues in oncology

Study Identifies Mechanism Behind Genetic Abnormality That Accelerates Growth of Ewing Sarcoma

The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes, both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. The findings by Riggi et al, published in Cancer Cell, may lead to new...

sarcoma
issues in oncology

Gene Sequencing Projects Link Two Mutations to Ewing Sarcoma Subtype With Poor Prognosis

An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma and that define a subtype of the cancer associated with reduced survival. The research, conducted by the St. Jude Children’s Research Hospital-Washington University...

sarcoma

Shorter-Duration Therapy Including Lower-Dose Cyclophosphamide Preserves Efficacy in Newly Diagnosed Low-Risk Rhabdomyosarcoma

Intergroup Rhabdomyosarcoma Study Group (IRSG) studies have shown improved failure-free survival with VAC (vincristine, dactinomycin, and cyclophosphamide) given with a total cumulative cyclophosphamide dose of 26.4 g/m2 compared with VA (vincristine and dactinomycin) in patients with subset 1...

gynecologic cancer
sarcoma

Low Mitotic Count Is an Independent Predictor of Survival in Women With Recurrent Uterine Leiomyosarcoma

Although low mitotic count, surgery, and disease-free interval of more than 6 months were associated with improved survival in women with recurrent or persistent uterine leiomyosarcoma, only low number of mitoses was identified as an independent predictor of survival post relapse, according to...

sarcoma

Reduced Local Recurrence With Intensity-Modulated vs External-Beam Radiation Therapy in Primary Soft-Tissue Sarcomas of the Extremity

There are no large-scale direct comparisons of outcomes with intensity-modulated radiation therapy vs conventional external-beam radiation therapy in patients with soft-tissue sarcoma of the extremity. In a single-institution experience reported in the Journal of Clinical Oncology, Folkert et al at ...

sarcoma

Phase II Study Shows Activity of Hypoxia-Activated Alkylating Prodrug in Combination With Doxorubicin in Advanced Soft-Tissue Sarcoma

In a phase II study reported in the Journal of Clinical Oncology, Chawla et al found that the combination of a hypoxia-activated alkylating prodrug (TH-302) and doxorubicin was active in first-line treatment of advanced soft-tissue sarcoma. TH-302 is a prodrug of the cytotoxic alkylating agent...

sarcoma

Cyclophosphamide Noninferior to Ifosfamide as Part of Consolidation Treatment in Standard-Risk Ewing Sarcoma

In a European phase III noninferiority trial (Euro-EWING99-R1) reported in the Journal of Clinical Oncology, Le Deley et al found that cyclophosphamide was noninferior in event-free survival vs ifosfamide in combination with vincristine/dactinomycin as consolidation therapy in patients with...

multiple myeloma
sarcoma

Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones

A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent...

sarcoma
issues in oncology

Tumor-Suppressor Gene TP53 Mutated in 90% of Osteosarcomas

The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project found mutations in the tumor-suppressor gene TP53 in 90% of osteosarcomas, suggesting the alteration plays a key role early in development of the bone cancer. The study by Chen et al was...

sarcoma

Long-Term Follow-up Shows Surgery Plus Radiation Offers Mixed Results in Soft-Tissue Sarcoma

Adjuvant radiation following surgery for soft-tissue sarcoma of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...

sarcoma

No Overall Survival Benefit of First-Line Doxorubicin Plus Ifosfamide vs Doxorubicin Alone in Advanced Soft-Tissue Sarcoma

In the open-label, phase III EORTC 62012 trial reported in The Lancet Oncology, Judson et al found that doxorubicin plus ifosfamide was not associated with any overall survival advantage compared with doxorubicin alone in patients with advanced or metastatic soft-tissue sarcoma. Progression-free...

sarcoma

Carbon Ion Radiotherapy Safe and Effective for Treating Inoperable Spinal Tumors

A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. The study, published online in Cancer, indicates that the treatment is a promising alternative for patients whose spinal tumors...

sarcoma

Loss of MicroRNA Decoy Might Contribute to Development of Soft-Tissue Sarcoma

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other...

sarcoma

Nearly Half of Sarcoma Surgeries Performed by Nononcologists

Nearly half the surgical procedures for sarcoma done at 85 academic medical centers were performed by surgeons untrained in oncology, according to national data analyzed by researchers from the University of California Davis Medical Center, Sacramento. Orthopedic oncologists and surgical...

sarcoma

Experimental Drug Beneficial in NIH Trial to Treat a Rare Sarcoma

Patients with advanced alveolar soft part sarcoma achieved some control of their disease using the experimental anticancer drug cediranib. The results from this largest clinical trial on alveolar soft part sarcoma to date were published online ahead of print on April 29, 2013, in the Journal of...

Advertisement

Advertisement

;
Advertisement